Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep217 | Reproduction, endocrine disruptors and signalling | ECE2015

Subclinical hypothyroidism in patients with polycystic ovary syndrome

Yasar Hamiyet Yilmaz , Topaloglu Omercan , Demirpence Mustafa , Ceyhan Banu Ozturk

Objective: Polycystic ovary syndrome (PCOS) is a common endocrine metabolic disorder that affects 5–10% of women of reproductive age. In various studies, it was found to be associated with subclinical hypothyroidism. Serum TSH levels were also reported to be increased in obese individuals. In order to define the impact of obesity on the subclinical hypothyroidism observed in patients with PCOS, we aimed to investigate subclinical hypothyroidism both in lean and overweight...

ea0014p46 | (1) | ECE2007

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acorbose in type 2 diabetes

Yilmaz Hamiyet , Gursoy Alptekin , Sahin Mustafa , Tutuncu Neslihan Bascil , Demirag Nilgun Guvener

The aim of this study was to compare the efficacy of treatment with insulin alone, insulin plus acarbose, insulin plus metformin or insulin plus rosiglitazone in type 2 diabetic subjects who were previously on insulin monotherapy, and to evaluate the effects of these treatments on cardiovascular risk factors including lipid profile, C-reactive protein (CRP) and fibrinogen. Sixty-six poorly controlled type 2 diabetic patients on insulin monotherapy were involved. They were rand...

ea0014p306 | (1) | ECE2007

Radioactive iodine in the treatment of type 2 amiodarone-induced thyrotoxicosis

Gursoy Alptekin , Bascil Tutuncu Neslihan , Gencoglu Arzu , Yilmaz Hamiyet , Nar Demirer Asli , Guvener Demirag Nilgun

Objective: Amiodarone-induced thyrotoxicosis (AIT) is usually classified into 2 types (type 1, in which a high iodine content triggers the autonomous production of thyroid hormone; and type 2, in which destructive thyroiditis causes the release of preformed thyroid hormone). A mixed form of AIT has also been also described. AIT is a difficult management problem that sometimes requires ablative thyroid therapy. The use of radioactive iodine (RAI) therapy in patients with type 1...

ea0037gp.19.01 | Pituitary–Acromegaly | ECE2015

Coagulation parameters and platelet function analysis in patients with acromegaly

Yasar Hamiyet Yilmaz , Demirpence Mustafa , Colak Ayfer , Ceyhan Banu Ozturk , Temel Yusuf , Simsek Nese , Karademirci Ismail , Bozkurt Umit

Objective: Acromegaly is associated with increased cardiovascular morbidity and mortality. But the data about the evaluation of coagulation and fibrinolysis in acromegalic patients is very limited and to our knowledge, platelet function analysis has never been investigated. So we aimed to investigate the levels of protein C, protein S, fibrinogen, antithrombin 3, and platelet function analysis in patients with acromegaly.Methods: Thirty-nine patients wit...

ea0056p812 | Pituitary - Clinical | ECE2018

Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?

Demirpence Mustafa , Guler Asli , Yilmaz Hamiyet , Sayin Ahmet , Pekcevik Yeliz , Turkon Hakan , Colak Ayfer , Ari Elif Merve , Aslanipour Behnaz , Kocabas Gokcen Unal , Calan Mehmet

Purpose: Acromegaly, an uncommon disease, is existed in the result of over production of growth hormone (GH). It is associated with increased cardiovascular risk factors and metabolic abnormalities. Urotensin II (UII), a secreted vasoactive peptide hormone, plays an essential role in the regulation of vascular tone, glucose metabolism and atherosclerosis. UII belonging to somatostatin superfamily activates somatostatin receptors as well. The aim of this study was to ascertain ...